Si­lence Ther­a­peu­tics wants to list on Nas­daq while pur­su­ing new deals; Sur­face On­col­o­gy inks lat­est Keytru­da col­lab­o­ra­tion

Sur­face On­col­o­gy $SURF has joined the long line­up of biotechs to match one of their drugs with Mer­ck’s pow­er­house fran­chise ther­a­py Keytru­da. The biotech will col­lab­o­rate with Mer­ck on com­bin­ing Sur­face’s CD39-tar­get­ed SRF617 with the check­point in a Phase I/Ib in sol­id tu­mors.

Si­lence Ther­a­peu­tics — list­ed in Lon­don as $SLN — is jump­ing the At­lantic to Nas­daq. The biotech struck a deal with As­traZeneca re­cent­ly, and now wants to add to its list of col­lab­o­ra­tions. In a state­ment to­day, the com­pa­ny not­ed: “Fol­low­ing the re­cent an­nounce­ment of the mul­ti-tar­get As­traZeneca col­lab­o­ra­tion in March, the Com­pa­ny con­tin­ues to hold dis­cus­sions with a num­ber of third par­ties re­gard­ing pos­si­ble part­ner­ship and col­lab­o­ra­tion op­por­tu­ni­ties. Ac­cord­ing­ly, the Com­pa­ny is strength­en­ing its Busi­ness and Al­liance Man­age­ment ca­pa­bil­i­ty un­der the lead­er­ship of John Straf­ford, VP, Busi­ness De­vel­op­ment, with a view to ac­com­mo­dat­ing an ex­pan­sion of its ex­ist­ing third-par­ty re­la­tion­ships and, as ap­pro­pri­ate, ad­di­tion­al col­lab­o­ra­tions.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.